Feb 16, 2018 5:24pm EST Emerald Health, Strategic Majority Investor in Nemus Bioscience, Completes Final Closing of Private Placement Investment Ahead of Schedule
Feb 07, 2018 8:30am EST NEMUS Bioscience to Participate in BIO CEO Investor Conference to Provide Ophthalmology-Focused Pipeline Review
Jan 19, 2018 8:30am EST Nemus Secures Emerald Health as Strategic Majority Investor to help Advance Clinical Development of Novel Cannabinoid-based Therapeutics
Dec 29, 2017 8:30am EST Nemus Bioscience Announces Closing of Convertible Bridge Loan and Anticipated Equity Financing
Nov 09, 2017 8:30am EST Nemus Bioscience Files Arbitration Petition Against Schneider Finance, LLC and SB Securities, Ltd. for Failure to Close $20 Million Financing and Failure to Honor Guarantee
Nov 06, 2017 8:30am EST NEMUS Bioscience Announces Presentation of CBD-analogue Therapeutic Data Related to Neuropathic Pain (NB2111) and Ocular Diseases (NB2222) at Upcoming Scientific Meetings
Oct 13, 2017 8:00am EDT NEMUS Bioscience Provides Further Update on Previously Announced $20 Million Schneider Financing
Aug 07, 2017 8:30am EDT NEMUS Bioscience Announces Presentation of CBD-analogue (NB2222) Ocular Data at the AAPS 2017 Annual Meeting
Aug 02, 2017 8:30am EDT Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference
